Cantargia AB (STO:CANTA), a biotechnology company that is developing antibody-based treatments for life-threatening diseases, on Tuesday reported that interim results from its clinical phase I/II trial of lead candidate CAN04 (nidanilimab) will be presented in a poster presentation at the ESMO Congress 2018 in Munich, Germany, on 20 October 2018.

This poster presentation, with the title 'A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumours', will be given by the coordinating investigator Professor Ahmad Awada, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

This poster is scheduled to be presented during the Poster Display session on 20 October 2001, from 12:30 hours to 13:30 hours.

Reportedly, the primary objective of the phase I part of CANFOUR was to assess safety and tolerability of weekly CAN04 in order to define the maximum tolerated dose/recommended phase 2 dose. Patients with relapsed or refractory non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), breast or colorectal cancer were included in the initial part of the trial using a 3+3 dose escalation design.

The abstract, with interim data from submission in May 2018, showed that CAN04 demonstrated a manageable safety profile up to 3 mg/kg with no dose limiting toxicity observed.

According to the company, the poster will include additional data as obtained until September 2018. The poster will be published in parallel with the presentation on 20 October 2018 on Cantargia's website, https://www.cantargia.com.

In August 2018, Cantargia had announced that 15 patients had been treated and CAN04 showed a good safety profile. A few more patients will be treated to establish maximum tolerated or recommended dose, the company added.

Also, in the phase IIa part of the study, which is expected to start in Q4 2018, the number of clinical sites will be increased.